Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05075330 · ClinicalTrials.gov registry record · NA
SMART Trial: Community Stigma Reduction
A NA study, sponsored by Karen Derefinko, PhD.
- Completed
- Registry status
- NA
- Development phase
- 199
- Enrollment target
NCT05075330: Completed NA study, sponsored by Karen Derefinko, PhD.
NCT05075330 is a NA study that has completed, run by Karen Derefinko, PhD. The registered enrollment target is 199 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05075330, a NA study, has completed, sponsored by Karen Derefinko, PhD.
- COMPLETED
- Registry status
- NA
- Development phase
- 199 participants
- Enrollment target
Study Summary
The goal of this project is to engage community members from two low-income African American communities (N=200) in a survey study that assesses stigma toward those with Opioid Use Disorder (OUD). Those from the intervention community will be subject to a stigma reduction campaign via billboards. Those from the control community will not. Stigma will be re-assessed following the period of the campaign.
Primary Outcome
Pre- and post-intervention stigma assessments using the Exposure to Drug Users Index, Drug Use Stigmatization Scale, and the Stigma of Drug Users Scale
Interventions
- BEHAVIORAL Opioid Use Disorder Stigma Reduction
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 199 participants |
| Start Date | 2021-06-16 |
| Est. Completion | 2021-08-19 |
| Phase | NA |
What the finished NCT05075330 record still lists
NCT05075330 is an interventional study that assigns participants to a tested intervention. The registered 199 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (86% lower).
The record links to 0 conditions, and to 1 intervention - of which Opioid Use Disorder Stigma Reduction is the first listed.
NCT05075330 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05075330 about?
NCT05075330 is a clinical study titled "SMART Trial: Community Stigma Reduction". The goal of this project is to engage community members from two low-income African American communities (N=200) in a survey study that assesses stigma toward those with Opioid Use Disorder (OUD). Those from the intervention community will be subject to a stigma reduction campaign via billboards. Th...
What is the current status of trial NCT05075330?
This trial is currently completed. It is a NA study. The enrollment target is 199 participants. The study started on 2021-06-16. Estimated completion is 2021-08-19.
What interventions are being tested in trial NCT05075330?
The interventions under investigation include: Opioid Use Disorder Stigma Reduction (BEHAVIORAL).
Who is sponsoring clinical trial NCT05075330?
This trial is sponsored by Karen Derefinko, PhD, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05075330's enrollment target sits among peer trials
199 567th of 2000 higher than 1,434 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04312126 · 199 participants
The Beneficial Effects of Naps on Motor Learning
- NCT04951622 · 199 participants · Phase 3
A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- NCT06474533 · 199 participants
Fluoroethyltyrosine for the Evaluation of Intracranial Neoplasm
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI